Item 7.01. Regulation FD Disclosure.

On February 6, 2023, Context Therapeutics Inc. (the "Company") issued a press release to provide additional preliminary data regarding a clinical trial involving one of the Company's product candidates. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

On February 6, 2023, the Company also updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the corporate presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.




Item 9.01. Exhibits.

(d) Exhibits

Exhibit No.              Description
                           Press Release issued by Context Therapeutics Inc., dated
99.1                     February 6, 2023
                           Context Therapeutics Inc. Corporate Presentation - February
99.2                     2023
                         Cover Page Interactive Data File (embedded within the inline
104                      XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses